Shots:

• Evoq to receive ~$240M up front & milestones along with royalties on the sales of therapies emerges from the collaboration
• The companies collaborated on preclinical development- while Amgen will be responsible for clinical development and commercialization
• The collaboration will bolster Amgen’s autoimmune offerings as its portfolio contains innovative medicines- including Otezla and Enbrel- and biosimilar products- such as Amgevita (a biosimilar to Humira) and Avsola (a biosimilar to Remicade)

 ­ Ref: PRNewswire | Image: Amgen